Physician profile
Umer A Ansari
NPI 1215469846
$1,146.42
in general payments reported to CMS, 2019-2025
18 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $167 · 2024: $775 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,131 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,131.15 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $317.04 | 2024-2025 | |
| Glaxosmithkline, LLC. | $123.87 | 2024 | Arexvy |
| Astrazeneca Pharmaceuticals LP | $91.43 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $90.18 | 2023-2024 | Otezla, Enbrel |
| Lilly USA, LLC | $84.71 | 2024-2025 | Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $78.71 | 2023-2024 | Sotyktu |
| Genzyme Corporation | $76.65 | 2023-2025 | |
| Baxter Healthcare | $39.49 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Regeneron Healthcare Solutions, INC. | $37.15 | 2024-2025 | Dupixent |
| Galderma Laboratories, L.P. | $35.49 | 2023-2024 | Aklief, Epsolay, Twyneo |
| Sanofi-Aventis U.S. LLC | $25.46 | 2024 | |
| Ucb, INC. | $23.43 | 2024 | Bimzelx |
| Janssen Biotech, INC. | $22.98 | 2024 | Tremfya |
| Verrica Pharmaceuticals INC. | $21.82 | 2024 | Ycanth |
| Novo Nordisk INC | $21.68 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20.97 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.09 | 2024 | Xifaxan |
| Pfizer INC. | $15.27 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umer Ansari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.